Medicure (MPH) Stock Price, News & Analysis

Company Overview

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Key Stats

• Today's Range: C$0.67 to C$0.81
• 50-Day Range: C$0.67 to C$0.90
• 52-Week Range: C$0.67 to C$1.26
• Volume: 2,500 shs
• Average Volume: 4,658 shs
• Market Capitalization: C$6.99 million
• P/E Ratio: N/A
• Dividend Yield: 2.24%
• Price Target: N/A
• Consensus Rating: N/A

MPH Stock Analysis - Frequently Asked Questions

How have MPH shares performed this year?

Medicure's stock was trading at C$0.88 at the beginning of the year. Since then, MPH stock has decreased by 23.9% and is now trading at C$0.67.
View the best growth stocks for 2025 here.

How were Medicure's earnings last quarter?

Medicure Inc. (CVE:MPH) posted its earnings results on Wednesday, May, 24th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.37. The company had revenue of $8.71 million for the quarter, compared to analysts' expectations of $14.50 million. Medicure had a negative net margin of 9.65% and a negative trailing twelve-month return on equity of 10.18%.

How do I buy shares of Medicure?

Shares of MPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Medicure own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicure investors own include Dollarama (DOL), Alimentation Couche-Tard (ATD.B), Canoe EIT Income Fund (ENDTF), Allena Pharmaceuticals (ALNA), Hudbay Minerals (HBM), ProMetic Life Sciences (PLI) and Athersys (ATHX).

Company Calendar

• Last Earnings: 5/24/2017
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: CVE:MPH
• CUSIP: N/A
• CIK: N/A
• Web: www.medicure.com
• Phone: +1-204-4877412
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.26
• P/E Growth: N/A
• Net Income: C$-2,033,997.47
• Net Margins: -9.65%
• Pretax Margin: N/A
• Return on Equity: -10.18%
• Return on Assets: -5.63%

Debt

• Debt-to-Equity Ratio: 4.65
• Current Ratio: 2.03
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: C$21.08 million
• Price / Sales: 0.33
• Cash Flow: C$0.27 per share
• Price / Cash Flow: 2.49
• Book Value: C$1.91 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 10,436,300
• Free Float: N/A
• Market Cap: C$6.99 million
• Optionable: Not Optionable
• Beta: 0.90